Peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS) is now considered a heterogeneous group of distinct molecular subtypes with varied natural history and clinical outcome. Although the standard treatment approach remains the same for all subtypes of PTCL-NOS, these findings will have significant impact on the management of patients with PTCL-NOS as important evidence from clinical trials get translated into routine clinical practice.